Flexion Therapeutics Inc (FLXN): Michael D. Clayman , CEO of Flexion Therapeutics Inc purchased 2,000 shares on May 16, 2016. The Insider buying transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $9.51 per share for a total value of $19,025.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 17, 2016, Neil Bodick (Chief Medical Officer) purchased 1,250 shares at $9.40 per share price.On Sep 14, 2015, C Ann Merrifield (director) purchased 1,000 shares at $23.00 per share price.Also, On Jun 22, 2015, A/s Novo (10% owner) sold 150,000 shares at $20.71 per share price.On Jan 22, 2015, Partners Sas Sofinnova (10% owner) sold 10,000 shares at $20.00 per share price.
Flexion Therapeutics Inc: On Monday, May 16, 2016 heightened volatility was witnessed in Flexion Therapeutics Inc which led to swings in the share price. The shares opened for trading at $8.83 and hit $9.78 on the upside , eventually ending the session at $9.67, with a gain of 10.51% or 0.92 points. The heightened volatility saw the trading volume jump to 2,47,973 shares. The 52-week high of the share price is $29.09 and the company has a market cap of $209 M . The 52-week low of the share price is at $7.56.
Company has been under the radar of several Street Analysts.Flexion Therapeutics Inc is Resumed by Wells Fargo to Outperform. The Rating was issued on May 3, 2016.
Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.